Arcus Biosciences (NYSE:RCUS) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBob Goeltz - CFODaniel Bronder - Equity Research AssociateHolli Kolkey - VP of Corporate AffairsJen Jarret - COOJonathan Miller - Managing DirectorJuan Jaen - President and Co-FounderRichard Marcus - CMOSalim Syed - Managing DirectorTerry Rosen - CEOYigal Nochomovitz - Director, Biotech Equity ResearchConference Call ParticipantsEmily Bodnar - Biotech Equity Research AnalystNone - AnalystNone - AnalystNone ...

Arcus Biosciences (NYSE:RCUS) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBob Goeltz - CFOHolli Kolkey - VP of Corporate AffairsJen Scott - Executive DirectorJonathan Miller - Managing DirectorJuan Jaen - President and Co-FounderLi Watsek - DirectorRichard Marcus - CMOSalim Syed - Managing DirectorTerry Rosen - CEOYigal Nochomovitz - Director, Biotech Equity ResearchConference Call ParticipantsEmily Bodnar - Biotech Equity Research AnalystNone - AnalystNone - AnalystNone - Analys ...

Arcus Biosciences (NYSE:RCUS) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker1Welcome everyone. The Arcus Biosciences full year and fourth quarter 2025 earnings and results call will begin shortly. In the meantime, if you would like to pre-register to ask a question, please press Star followed by one on your telephone keypad. If you change your mind, please press Star followed by two. Hello everyone, thank you for joining the Arcus Biosciences full year and fourth quarter 2025 earnings and finan ...

Full Year 2025 Investor Presentation Oncology and Immunology Portfolio Summary February 25, 2026 Forward-looking Statements/Safe Harbor Forward-Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this presentation that are not historical facts are forward-looking statements, including, without l ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________________________________ FORM 10-K __________________________________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tr ...

Financial Performance - Arcus reported revenues of $33 million for Q4 2025, a decrease from $36 million in Q4 2024, with $23 million from Gilead collaboration and $7 million from Taiho's option exercise[17]. - The net loss for Q4 2025 was $106 million, compared to a net loss of $94 million in Q4 2024[17]. - Total revenues for Q4 2025 were $33 million, a decrease of 8.3% from $36 million in Q4 2024[22]. - Basic and diluted net loss per share improved slightly to $(0.89) in Q4 2025 from $(1.03) in Q4 2024[22]. - GAAP revenue for the full year 2026 is projected to be between $45 million and $55 million[17]. Research and Development - Research and Development (R&D) expenses increased to $121 million in Q4 2025 from $111 million in Q4 2024, driven by higher late-stage development costs[17]. - Arcus anticipates a decrease in R&D expenses for the full year 2026 compared to 2025, influenced by the results of the futility analysis of the STAR-121 study[17]. - Research and development expenses for the year ended December 31, 2025, were $523 million, up from $448 million in 2024, indicating a continued focus on innovation[22]. - The Phase 3 PEAK-1 study for casdatifan is currently enrolling globally, targeting a peak sales opportunity exceeding $5 billion in the IO-experienced and first-line settings[3]. - Casdatifan demonstrated a median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% in late-line kidney cancer[6]. - Arcus plans to initiate a Phase 3 study for casdatifan in a TKI-free combination by the end of 2026, focusing on first-line metastatic settings[6]. - The company expects to advance its first inflammation program, a potential oral MRGPRX2 antagonist, into clinical development in 2026[12]. Financial Position - Arcus has $1.0 billion in cash, cash equivalents, and marketable securities as of December 31, 2025, up from $992 million in 2024, providing a cash runway until at least the second half of 2028[17]. - Cash, cash equivalents, and marketable securities increased to $1,010 million as of December 31, 2025, compared to $992 million a year earlier[24]. - Total assets decreased to $1,139 million in 2025 from $1,150 million in 2024[24]. - Total liabilities decreased significantly from $665 million in 2024 to $508 million in 2025, indicating improved financial health[24]. - Total stockholders' equity increased to $631 million in 2025, up from $485 million in 2024, reflecting a strong capital position[24]. Operating Expenses - Total operating expenses rose to $147 million in Q4 2025, up from $139 million in Q4 2024, primarily driven by increased research and development costs[22].

Core Viewpoint - Arcus Biosciences, Inc. (NYSE:RCUS) is experiencing mixed analyst ratings, with recent downgrades and upgrades reflecting uncertainty in its product differentiation and upcoming clinical data readouts [1][2]. Analyst Ratings - Wells Fargo downgraded Arcus Biosciences from Overweight to Equal Weight, lowering the price target from $30 to $23 due to unclear differentiation for Welireg and potential negative impacts from upcoming data readouts [1]. - Bank of America Securities maintained a Hold rating with a price target of $26 [2]. - Goldman Sachs upgraded the stock from Neutral to Buy, raising the price target from $16 to $28, highlighting the potential of the company's lead asset, casdatifan [2]. Product Development - Casdatifan is a selective HIF-2alpha inhibitor being developed for advanced clear cell renal cell carcinoma, with an estimated total addressable market of approximately 17,400 patients in the US/EU and projected risk-adjusted peak sales of about $1.7 billion [3]. - Phase 1 results for the ARC-20 trial showed overall response rates of 31% for the mono regimen and 46% for the combination regimen, with expectations for further improvement as the trial matures [3]. Company Overview - Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing immunotherapies, competing in the biotechnology and pharmaceutical sectors [4].

Group 1 - Arcus Biosciences, Inc. (RCUS) shares have increased by 1.2% over the past four weeks, closing at $21.96, with a mean price target of $34.6 indicating a potential upside of 57.6% [1] - The average of 10 short-term price targets ranges from a low of $20.00 to a high of $52.00, with a standard deviation of $10.17, suggesting variability in analyst estimates [2] - Analysts are optimistic about RCUS's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1% over the last 30 days, with one estimate moving higher and no negative revisions [12] - RCUS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide guidance on the direction of price movement [14]

Core Viewpoint - The trend of Chinese innovative drugs going global continues to gain momentum in 2026, with local pharmaceutical companies like Rongchang Biologics achieving significant overseas licensing agreements, marking a shift from simple product output and price competition to a new phase of value competition based on systematic R&D and original innovation [1][2][3] Group 1: Collaboration Models - Multiple local pharmaceutical companies, including Rongchang Biologics, have recently signed significant overseas licensing agreements, indicating a diversification in collaboration models [2] - Rongchang Biologics signed an exclusive licensing agreement with AbbVie for its PD-1/VEGF bispecific antibody drug RC148, receiving an upfront payment of $650 million and potential milestone payments up to $4.95 billion, along with double-digit royalties on net sales outside Greater China [2] - The collaboration aims to accelerate the global development and commercialization of RC148, enhancing Rongchang Biologics' brand value and international influence [2] Group 2: Market Trends and Characteristics - The overseas licensing of Chinese innovative drugs has shown significant characteristics, including a shift towards diverse collaboration models and a focus on the clinical value of drugs rather than just price advantages [3] - Oncology drugs are the primary focus for overseas licensing, with a few endocrine and autoimmune drugs also achieving international collaborations [3] - The total value of overseas licensing transactions for Chinese innovative drugs exceeded $130 billion in 2025, with over 150 transactions, marking a historical high [4] Group 3: Policy and Support - The National Medical Insurance Administration is actively supporting the "going global" strategy for Chinese pharmaceuticals, aiming to enhance the internationalization of the Chinese pharmaceutical industry [5] - The Ministry of Industry and Information Technology is planning to develop a pharmaceutical industry cooperation platform, facilitating the transition of Chinese pharmaceutical companies from exporting raw materials to innovative drugs and high-end medical devices [6] Group 4: Future Outlook - The overall trend of Chinese innovative drugs going global is expected to remain strong in 2026, driven by improved core capabilities and the global demand for innovation [7] - The oncology sector will continue to be the main battlefield, while metabolic and cardiovascular drug fields are anticipated to see increased international transactions [7] - The industry is shifting from a general explosion to a layered prosperity, with only assets that demonstrate global differentiation and clinical certainty likely to secure high-quality orders [7]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]